Does Betaseron Cause Depression?
Betaseron (interferon beta-1b), a treatment for relapsing multiple sclerosis, lists depression as a reported side effect in clinical trials and post-marketing data. In pivotal trials, depression occurred in 17-30% of patients on Betaseron versus 14-19% on placebo, though causality isn't definitively proven—MS itself increases depression risk.[1][2]
How Common Is Depression on Betaseron?
Rates vary by study:
- Early trials (e.g., IFNB Multiple Sclerosis Study Group): 20-30% incidence, similar to natural MS progression.[1]
- Long-term data: Up to 44% in some cohorts, but often linked to disease burden rather than the drug alone.[3]
No dose-response link; symptoms typically emerge within months of starting.
What Do Patients Report About Mood Changes?
Real-world feedback from MS forums and registries notes mood dips, irritability, or depressive episodes starting 1-3 months in, sometimes resolving with dose adjustment or antidepressants. Suicidal ideation is rare (0.5-2%) but flagged in labeling—monitor closely if history of depression.[2][4]
Why Might Betaseron Affect Mood?
Interferon betas induce cytokines (e.g., IFN-gamma), mimicking flu-like states that can trigger neuropsychiatric effects. MS brain inflammation compounds this; animal models show interferons alter serotonin pathways.[5]
Compared to Other MS Drugs
| Drug | Depression Rate | Notes |
|------|-----------------|-------|
| Betaseron | 17-30% | Higher early on[1] |
| Avonex (interferon beta-1a) | 20-25% | Similar profile[6] |
| Tecfidera | 10-15% | Lower mood risk[7] |
| Ocrevus | <10% | Minimal psychiatric effects[8] |
Switching to oral DMTs often reduces symptoms.
What If Depression Starts on Betaseron?
Discontinue if severe; guidelines recommend SSRIs (e.g., sertraline) alongside. FDA black-box warns of suicide risk with interferons—report to prescriber immediately. No generic yet; Bayer holds patents through 2028 in key markets.[9]DrugPatentWatch.com
[1]: FDA Betaseron Label (2023)
[2]: Lancet Neurol. 2003;2:503-12
[3]: Mult. Scler. J. 2015;21:1024-33
[4]: PatientsLikeMe MS data
[5]: J. Neurosci. 2001;21:RC175
[6]: Neurology 1996;47:889-94
[7]: NEJM 2012;367:1098-107
[8]: NEJM 2017;376:221-34
[9]: EMA Summary of Product Characteristics